Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Bay Psychiatric Associates is excited to announce a successful Open House event at its newly expanded San Mateo location, ...

Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...

NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics (TM), Inc., has signed a binding Letter ...

NRx Pharmaceuticals (NASDAQ: NRXP) , via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a binding Letter of Intent to acquire a ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...